Sikarin PCL (BKK:SKR) Beta: 0.0957 (As of Jul. 07, 2026)


BKK:SKR Sikarin PCL BKK:SKR
90 GF Score
Price ฿7.90
GF Value ฿9.11
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sikarin PCL Beta?

Sikarin PCL BKK:SKR 90 Beta is 0.0957 as of Jul. 07, 2026. GuruFocus rates BKK:SKR with a GF Score™ of 90/100 and a GF Value™ of ฿9.11 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-07), Sikarin PCL's Beta is 0.0957.


Sikarin PCL  (BKK:SKR) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Sikarin PCL Beta Related Terms


Sikarin PCL Beta Historical Data

* Premium members only.

The historical data trend for Sikarin PCL's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sikarin PCL Beta Chart

Sikarin PCL Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.53 1.29 0.75 0.33

Sikarin PCL Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.46 0.32 0.33 0.07

BKK:SKR vs HCA, THC, DVA: Beta Comparison

For the Medical Care Facilities subindustry, Sikarin PCL's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sikarin PCL Beta vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sikarin PCL's Beta distribution charts can be found below:

* The bar in red indicates where Sikarin PCL's Beta falls into.


BKK:SKR
90GF Score
Sikarin PCL BKK:SKR
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sikarin PCL Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0957 mean?
Sikarin PCL (BKK:SKR) has a Beta of 0.0957 as of Jul. 07, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sikarin PCL and its competitors.
Is Sikarin PCL's Beta too high?
Sikarin PCL's current Beta is 0.0957. Overall, Sikarin PCL has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sikarin PCL's Beta compare to HCA and THC?
Sikarin PCL's Beta of 0.0957 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sikarin PCL and its competitors. Sikarin PCL's current Beta is 0.0957. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sikarin PCL stock overvalued right now?
Based on GuruFocus' analysis, Sikarin PCL (BKK:SKR) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿9.11, compared to a current price of ฿7.90 — trading 13.3% below its estimated fair value. The current Beta is 0.0957. Sikarin PCL's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Sikarin PCL (BKK:SKR), the current Beta is 0.0957 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sikarin PCL (BKK:SKR) Overvalued in 2026?

Based on GuruFocus' analysis, Sikarin PCL stock appears to be undervalued. The current stock price of ฿7.90 is trading 13.3% below its estimated GF Value™ of ฿9.11. GuruFocus considers Sikarin PCL to be Modestly Undervalued.

Key valuation signals for BKK:SKR:

  • Beta: 0.0957
  • GF Value™: ฿9.11 vs. price of ฿7.90 (13.3% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the BKK:SKR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sikarin PCL Business Description

Address 976, Lasalle Road, Bangna Tai Subdistrict, Bangna District, Bangkok, THA, 10260
SSikarin PCL provides general healthcare services and operates under the social security system. The Group has one main operating segment, which is providing healthcare services through private hospitals and hospitals affiliated with the social security system. The Group operates in a single geographical area, which is Thailand. Its services include medical centers, a pediatric center, a women's institute, a radiology center, a neurology center, a rehabilitation center, and an orthopedic center.
90GF Score

Get the complete analysis for BKK:SKR

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿7.90
Price
฿9.11
GF Value